Molnupiravir was developed in response to an urgent unmet need for an orally administered antiviral drug to prevent disease progression in patients with COVID-19. Dr Nagalingeswaran Kumarasamy (Voluntary Health Services Hospital, Chennai, Southern India) discusses the phase III study assessing the efficacy and safety of molnupiravir in Indian patients with mild SARS-CoV2 infection.
The abstract entitled: ‘Phase III Trial of Molnupiravir in Adults with Mild Sars-Cov-2 Infection in India’ (Abstract #101) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- Could you give us a brief overview of the Phase III Molnupiravir clinical trial in India, and the key study findings? (0:34)
- What questions remain unanswered and what will be the next steps for Molnupiravir as a treatment for COVID-19? (6:14)
Disclosures: Nagalingeswaran Kumarasamy has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022
Share this Video
Related Videos In COVID-19
Ruth Link-Gelles, IDWeek 2022: Efficacy of COVID-19 vaccination in paediatric populations
In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States. Interviews available in this series: Real world […]
Ruth Link-Gelles, IDWeek 2022: Real world effectiveness of paediatric COVID-19 vaccination
COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss real-world findings of […]
Christoph Boesecke: Impact of COVID-19 on the treatment of patients living with HIV
Key clinical highlights in HIV infection are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Christoph Boesecke (Infectious Diseases Specialist, Senior Lecturer, University of Bonn, Bonn, Germany). He discusses the delays caused by the COVID-19 pandemic and the impact that has had on the treatment of patients living with HIV. He also […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!